BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based
small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in
tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined
with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure
tolerability and safety, followed by a cohort expansion phase.